Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Mental Health Strategy 2024-2030

Executive Summary
 
We can all play a role in promoting and safeguarding mental health for all population groups and in supporting individuals going through difficult times. This strategy serves as a seven-year roadmap aimed at guiding the Ministry of Public Health and all relevant stakeholders while mobilizing efforts to improve mental health in Lebanon. In Lebanon, in particular, improving mental health also requires addressing the social, economic, and political factors that negatively impact mental well-being and hinder the recovery process.
 
The strategy was developed using a comprehensive approach to address key issues. First, an assessment of the mental health situation in the country was conducted, including the burden of diseases, needs, and an evaluation of the existing system’s ability to meet these needs. Previous efforts were also reviewed to identify areas that need to be maintained and those requiring improvement. Furthermore, consultations were held with experts and local stakeholders, including individuals with lived experiences, to help set strategic priorities. The strategy was also guided by international frameworks, including World Health Organization (WHO) guidelines and other evidence-based recommendations. Special care was taken to select approaches that are appropriate and adaptable to the local context. Finally, the strategy was published and made available to the public for feedback and revisions.
 
The strategy addresses all fundamental aspects of the mental health system to enhance overall mental well-being and prevent mental disorders, with a focus on the following key areas:
  • Raising awareness about mental health, reducing misconceptions, and implementing evidence-based interventions to prevent mental health issues. This includes emphasizing the importance of addressing political, social, and economic factors that influence mental health.
  • Empowering individuals by providing them with the resources, knowledge, and skills necessary to protect their mental well-being and ensuring access to available services when needed.
  • Ensuring that individuals with mental health disorders can access high-quality care whenever they need it, regardless of their place of residence.
  • Supporting healthcare providers and all professionals in the field by building their capacity based on evidence-based practices and helping them safeguard their own mental health.
  • Preventing and reducing harmful practices that violate human rights and quality standards in the provision of mental health services.
  • Enhancing data availability and conducting valuable research to guide and support efforts to improve mental health across the country.
  • Establishing legal frameworks, policies, and appropriate funding mechanisms to strengthen the mental health system.
  • Integrating the views, perspectives, and preferences of individuals with lived experiences in the design, development, and implementation of services, policies, and practices.
Specific actions have been planned for each of these key areas to ensure the necessary improvements in the country.
 

 
National Mental Health Strategy 2024-2030 (Please click on this link to download the document)
 
Theory of Change Map (Please click on this link to download the document)

Executive Summary (English, French, Arabic) 
 
    ...
    12
    ...
ATC Name B/G Ingredients Dosage Form Price
N05AA01 CHLORPROMAZINE G Chlorpromazine HCl - 50mg 50mg Tablet 332,761 L.L
C09DA04 CONVERIUM PLUS G Irbesartan - 300mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 395,090 L.L
M01AH05 CLINTON G Etoricoxib - 90mg 90mg Tablet, film coated 1,280,682 L.L
J01XB01 COLISTIMETHATE SODIQUE PANPHARMA G Colistimethate Sodium - 1.000.000IU 1.000.000IU Injectable powder for solution, Inhalation powder 6,392,659 L.L
M01AH05 CONSORT G Etoricoxib - 90mg 90mg Tablet, film coated 338,648 L.L
J01XB01 COLISTIN HIKMA G Colistimethate Sodium - 1MIU 1MIU Injectable powder for solution, Inhalation powder 903,062 L.L
M01AH05 COXIFLAM G Etoricoxib - 90mg 90mg Tablet, film coated 1,293,928 L.L
H01BB03 CARBETOCINA GP-PHARM G Carbetocin - 100mcg 100mcg Injectable solution 9,041,227 L.L
J01XB01 COLISTIN/NORMA G Colistimethate Sodium - 1MIU 1MIU Injectable solution 872,154 L.L
G01AA10 CLINDAMYCIN G Clindamycin - 100mg 100mg Ovule 712,876 L.L
J01XB01 COLIXIN G Colistimethate Sodium - 1,000,000IU 1,000,000IU Injectable powder for solution, Inhalation powder 20,296,042 L.L
R03BA01 CORTIS G Beclometasone dipropionate - 250mcg/actuation 250mcg/actuation Inhalation solution 674,609 L.L
J01XB01 COLISTIMETHATE G Colistimethate Sodium - 150mg 150mg Injectable powder for solution 38,239,924 L.L
M01AH05 CLINTON G Etoricoxib - 120mg 120mg Tablet, film coated 362,837 L.L
M01AH05 CONSORT G Etoricoxib - 120mg 120mg Tablet, film coated 309,084 L.L
M01AH05 COXIFLAM G Etoricoxib - 120mg 120mg Tablet, film coated 398,033 L.L
G01AF02 CANAGYN G Clotrimazole - 100mg 100mg Tablet 229,797 L.L
R03BA02 CORTAIR G Budesonide - 1mg/2ml 0.5mg/ml Inhalation suspension for nebuliser 1,209,458 L.L
C09DA06 CANDESARTAN / HYDROCHLOROTHIAZIDE BIOGARAN G Candesartan cilexetil - 16mg, Hydrochlorothiazide - 12.5mg Tablet 327,898 L.L
G01AF02 CANAGYN G Clotrimazole - 500mg 500mg Tablet 302,365 L.L
C09DA06 CANDESARTAN / HYDROCHLOROTHIAZIDE BIOGARAN G Candesartan cilexetil - 8mg, Hydrochlorothiazide - 12.5mg Tablet 327,898 L.L
N05AH02 CLOZAPINE PANPHARMA G Clozapine - 100mg 100mg Tablet, scored 808,993 L.L
C07AG02 CARVEDILOL ARROW G Carvedilol - 6.25mg 6.25mg Tablet, film coated, scored 364,181 L.L
C07AG02 CARVEDILOL ARROW G Carvedilol - 12.5mg 12.5mg Tablet, film coated, scored 364,181 L.L
L01BC01 CYTU G Cytarabine - 1000mg/10ml 1000mg/10ml Injectable solution 2,230,779 L.L
C07AG02 CARVEDILOL ARROW G Carvedilol - 25mg 25mg Tablet, film coated, scored 425,998 L.L
S01CA01 CO-AVAZIR G Tobramycin - 0.3%, Dexamethasone - 0.1% Drops suspension 193,513 L.L
J01DD08 CEFIX G Cefixime (trihydrate) - 100mg/5ml 100mg/5ml Powder for suspension 349,399 L.L
M02AA15 CLOFEN G Diclofenac sodium (diethylamine) - 10mg/g 1% Creamagel 210,983 L.L
J01DD08 CEFIX G Cefixime (trihydrate) - 100mg/5ml 100mg/5ml Powder for suspension 700,142 L.L
    ...
    12
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025